DUBLIN, November 9, 2016 /PRNewswire/ -- Research and Markets has announced the addition of the "US Market Report for Cochlear Implants 2017 - MedCore" report to their offering.
Manufacturers of cochlear implants will differ with the numbers of electrodes. The device provides a treatment option for those with hearing loss too severe (due to loss of cochlea sensory hair cells) to be treated with standard hearing aids, as well as those with damaged middle ears but viable cochleas, who are also unable to benefit from the use of standard hearing aids or from the latest models of high powered hearing instruments. In addition to adults, cochlear implants are especially beneficial to infants and very young children with single-sided deafness who, if treated early enough, are able to develop significantly better speech skills than if they were fit with a standard hearing aid later in life with the help of speech and language therapy. The improved speech and hearing ability offered by early cochlear implantation often results in better educational performance and a higher earning potential later in life. The surgery is typically followed up with post-cochlear implant aural rehabilitation, including an auditory verbal therapist, a speech language pathologist and a deaf educator. This unit sales trend is a result of both patient awareness and patient acceptance with respect to the benefits of cochlear implants. In addition, existing unilateral patients receiving second surgical implants (bilateral - on the other side of their ear) is becoming more common. The largest limiter of this market over previous years has been the product recalls that both Cochlear and Advanced Bionics underwent. However, both companies have sufficiently recovered from the drop in sales. While growth in this market had been lower than expected, 2015 marked a year of significant sales growth for Cochlear which helped drive the overall. It is expected that the growth rate will gradually stabilize throughout the remainder of the forecast.